… new adjuvants have received approval for use anywhere in the developed world. The vaccine
adjuvant monophosphoryl lipid … Instead, monophosphoryl lipid A s structure seems to have …

… derived from Salmonella minnesota R595, termed monophosphoryl lipid A (MPL), has been
… Assessment of the adjuvant characteristics of MPL has shown it to be an effective adjuvant …

… , alum and Freund's adjuvants had to be physically associated with the antigen in order to
be effective. Except for experimental investigations, LPS has not found uses as an adjuvant in …

… However, most adjuvants have adverse side effects and are therefore not accepted in … is a
potent adjuvant in vivo (4). The product obtained, referred to as monophosphoryl lipid A (MPL) …

… adjuvants in order to generate robust anti-tumor immune responses in humans. Many adjuvants
… toll-like receptors (TLRs) and promote effective uptake, processing and presentation of …

… In conclusion, our data indicate that MPLA is an effective adjuvant for pulmonary vaccines.
When delivered together with WIV influenza vaccine MPLA improves local and systemic …

… adjuvant is a practical way to improve the immunogenicity of inactivated rabies vaccines. In
this study, we found that monophosphoryl-lipid … vaccine is more effective in preventing rabies …

… adjuvant for this bacterial toxoid. On the contrary, no significant differences were observed
… adjuvanted with Alum + MLPA or MF59, and MF59 resulted the most effective adjuvant for TT …

… Taken together, our findings support the use of MPLA as an effective adjuvant to the rabies
vaccine and suggest that it could lead to the development of a new type of rabies vaccine. …

Animal models have shown the potential use of monophosphoryl lipid A (MPL®), a detoxified
bacterial lipopolysaccharide, as a vaccine adjuvant. Immunostimulatory activity with …